| Product Code: ETC9978322 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Transarterial Chemoembolization (TACE) Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Transarterial Chemoembolization (TACE) Market - Industry Life Cycle |
3.4 United States (US) Transarterial Chemoembolization (TACE) Market - Porter's Five Forces |
3.5 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume Share, By Procedure Type, 2021 & 2031F |
3.6 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.8 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 United States (US) Transarterial Chemoembolization (TACE) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of liver cancer in the United States |
4.2.2 Technological advancements leading to improved TACE procedures |
4.2.3 Growing awareness about the benefits of TACE as a minimally invasive treatment option |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and approval processes for TACE procedures |
4.3.2 High cost associated with TACE treatment |
4.3.3 Limited accessibility to TACE procedures in certain regions of the United States |
5 United States (US) Transarterial Chemoembolization (TACE) Market Trends |
6 United States (US) Transarterial Chemoembolization (TACE) Market, By Types |
6.1 United States (US) Transarterial Chemoembolization (TACE) Market, By Procedure Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Procedure Type, 2021- 2031F |
6.1.3 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Conventional TACE, 2021- 2031F |
6.1.4 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By DEB-TACE, 2021- 2031F |
6.2 United States (US) Transarterial Chemoembolization (TACE) Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Unresectable HCC, 2021- 2031F |
6.2.3 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Early-Stage HCC, 2021- 2031F |
6.3 United States (US) Transarterial Chemoembolization (TACE) Market, By Product Type |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Chemotherapeutic Agents, 2021- 2031F |
6.3.3 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Radiotherapeutic Agents, 2021- 2031F |
6.3.4 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Drug-eluting Particles, 2021- 2031F |
6.3.5 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Transarterial Chemoembolization (TACE) Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Surgical Centers, 2021- 2031F |
6.4.5 United States (US) Transarterial Chemoembolization (TACE) Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Transarterial Chemoembolization (TACE) Market Import-Export Trade Statistics |
7.1 United States (US) Transarterial Chemoembolization (TACE) Market Export to Major Countries |
7.2 United States (US) Transarterial Chemoembolization (TACE) Market Imports from Major Countries |
8 United States (US) Transarterial Chemoembolization (TACE) Market Key Performance Indicators |
8.1 Average waiting time for TACE procedures |
8.2 Number of healthcare facilities offering TACE services |
8.3 Patient satisfaction rate with TACE treatment |
8.4 Rate of adoption of TACE procedures in different demographics |
8.5 Survival rate post-TACE treatment |
9 United States (US) Transarterial Chemoembolization (TACE) Market - Opportunity Assessment |
9.1 United States (US) Transarterial Chemoembolization (TACE) Market Opportunity Assessment, By Procedure Type, 2021 & 2031F |
9.2 United States (US) Transarterial Chemoembolization (TACE) Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 United States (US) Transarterial Chemoembolization (TACE) Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.4 United States (US) Transarterial Chemoembolization (TACE) Market Opportunity Assessment, By Application, 2021 & 2031F |
10 United States (US) Transarterial Chemoembolization (TACE) Market - Competitive Landscape |
10.1 United States (US) Transarterial Chemoembolization (TACE) Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Transarterial Chemoembolization (TACE) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here